Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$266.11
$259.25
$197.81
▼
$495.55
$35.61B0.311.70 million shs1.43 million shs
argenex SE stock logo
ARGX
argenex
$1,033.15
$926.47
$661.85
▼
$1,072.75
$64.63B0.47289,955 shs125,055 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$827.72
$738.29
$541.00
▼
$859.34
$85.22B0.2685,989 shs561,135 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$546.12
$509.50
$374.17
▼
$560.25
$138.61B0.321.12 million shs803,262 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.00%+12.24%+21.40%-8.92%-41.13%
argenex SE stock logo
ARGX
argenex
0.00%+0.97%+19.43%+17.08%+37.61%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+4.22%+5.53%+35.39%+44.36%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.00%+0.82%+10.09%+23.29%+37.87%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$266.11
$259.25
$197.81
▼
$495.55
$35.61B0.311.70 million shs1.43 million shs
argenex SE stock logo
ARGX
argenex
$1,033.15
$926.47
$661.85
▼
$1,072.75
$64.63B0.47289,955 shs125,055 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$827.72
$738.29
$541.00
▼
$859.34
$85.22B0.2685,989 shs561,135 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$546.12
$509.50
$374.17
▼
$560.25
$138.61B0.321.12 million shs803,262 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.00%+12.24%+21.40%-8.92%-41.13%
argenex SE stock logo
ARGX
argenex
0.00%+0.97%+19.43%+17.08%+37.61%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+4.22%+5.53%+35.39%+44.36%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.00%+0.82%+10.09%+23.29%+37.87%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.88
Moderate Buy$386.1445.10% Upside
argenex SE stock logo
ARGX
argenex
2.88
Moderate Buy$1,158.6112.14% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.58
Moderate Buy$800.36-3.31% Downside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.96
Moderate Buy$569.524.29% Upside

Current Analyst Ratings Breakdown

Latest ALNY, VRTX, REGN, and ARGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
argenex SE stock logo
ARGX
argenex
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$1,150.00
9/2/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$455.00
9/1/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$665.00
9/1/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$653.00
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/31/2026
argenex SE stock logo
ARGX
argenex
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,230.00 ➝ $1,250.00
8/26/2026
argenex SE stock logo
ARGX
argenex
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,350.00 ➝ $1,415.00
8/26/2026
argenex SE stock logo
ARGX
argenex
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$960.00 ➝ $1,400.00
8/25/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$4.80B7.41$2.80 per share95.17$5.97 per share44.57
argenex SE stock logo
ARGX
argenex
$4.25B15.21$21.33 per share48.43$118.34 per share8.73
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.94$41.97 per share19.72$295.66 per share2.80
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.00B11.55$17.58 per share31.07$73.57 per share7.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3849.4627.43N/A15.26%84.93%14.30%10/29/2026 (Estimated)
argenex SE stock logo
ARGX
argenex
$1.29B$26.0439.6827.721.0732.19%43.59%36.66%N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4620.4616.381.6227.86%13.47%10.34%10/28/2026 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1831.7929.652.3735.00%23.09%16.72%11/2/2026 (Estimated)

Latest ALNY, VRTX, REGN, and ARGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
7/30/2026Q2 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.63$1.84+$0.21$1.21$1.32 billion$1.29 billion
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.45%N/A9.29%N/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest ALNY, VRTX, REGN, and ARGX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.46%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.74

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
argenex SE stock logo
ARGX
argenex
60.32%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
argenex SE stock logo
ARGX
argenex
2.43%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.80 million253.30 millionOptionable

Recent News About These Companies

VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 94,060 Vertex Pharmaceuticals Incorporated $VRTX
September 7 at 6:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-buys-shares-of-94060-vertex-pharmaceuticals-incorporated-vrtx-2026-09-07/
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Hsbc Holdings PLC
September 7 at 4:48 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-acquired-by-hsbc-holdings-plc-2026-09-07/
2,409 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Formuepleje A S
September 7 at 4:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-2409-shares-in-vertex-pharmaceuticals-incorporated-vrtx-purchased-by-formuepleje-a-s-2026-09-07/
California State Teachers Retirement System Buys 190,118,003 Shares of Vertex Pharmaceuticals Incorporated $VRTX
September 7 at 4:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-buys-190118003-shares-of-vertex-pharmaceuticals-incorporated-vrtx-2026-09-07/
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Amundi
September 7 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-purchased-by-amundi-2026-09-07/
Saudi Central Bank Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
September 6 at 5:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-saudi-central-bank-raises-stock-holdings-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-06/
AXQ Capital LP Buys New Holdings in Vertex Pharmaceuticals Incorporated $VRTX
September 5 at 3:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-axq-capital-lp-buys-new-holdings-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-05/
NEOS Investment Management LLC Purchases 19,219 Shares of Vertex Pharmaceuticals Incorporated $VRTX
September 4 at 5:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-neos-investment-management-llc-purchases-19219-shares-of-vertex-pharmaceuticals-incorporated-vrtx-2026-09-04/
Vertex Pharmaceuticals (NASDAQ:VRTX) Sets New 12-Month High - Here's What Happened
September 4 at 4:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003212
Nykredit A S Buys Shares of 248,068 Vertex Pharmaceuticals Incorporated $VRTX
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-buys-shares-of-248068-vertex-pharmaceuticals-incorporated-vrtx-2026-09-03/
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
September 2, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2983858/why-is-vertex-vrtx-up-14-4-since-last-earnings-report?cid=cs-stocknewsapi-ft-realtime_blog-2983858
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?
September 2, 2026  |  barchart.comhttps://www.barchart.com/story/news/4404399/how-is-vertex-pharmaceuticals-stock-performance-compared-to-other-biotech-stocks
Vertex Pharmaceuticals (NASDAQ:VRTX) Hits New 52-Week High - Should You Buy?
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vertex-pharmaceuticals-nasdaq-vrtx-hits-new-52-week-high-should-you-buy-2026-09-02/
Proficio Capital Partners LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-proficio-capital-partners-llc-takes-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-02/
Independence Bank of Kentucky Raises Position in Vertex Pharmaceuticals Incorporated $VRTX
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-independence-bank-of-kentucky-raises-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-02/
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks
September 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-vrtx-stock-trades-premium-010720573.html
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
September 1, 2026  |  investorshub.advfn.comhttps://investorshub.advfn.com/market-news/article/35430/vertex-completes-10-billion-crinetics-acquisition-adding-rare-endocrine-growth-platform
Goldman Sachs refreshes conviction lists on both sides of the Atlantic
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/goldman-sachs-refreshes-conviction-lists-172632169.html
Vertex Pharmaceuticals names Jonathan Poole to CFO role
September 1, 2026  |  msn.comhttps://www.msn.com/en-us/money/executive-leadership-and-management/vertex-pharmaceuticals-names-jonathan-poole-to-cfo-role/ar-AA2blk5q
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/oncoc4-appoints-dr-steve-chen-110000815.html
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertex-completes-acquisition-crinetics-pharmaceuticals-130300214.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$266.11 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

argenex stock logo

argenex NASDAQ:ARGX

$1,033.15 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$827.72 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$546.12 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas